No Detail Found!

HEP-NET OPINION ABOUT THE MANAGEMENT OF PATIENTS WITH CHRONIC HEPATITIS C IN PAKISTAN IN THE ERA OF AVAILABLE DIRECT ACTING ANTIVIRALS

Author(s)
Javed Iqbal Farooqi Lady Reading Hospital,Peshawar -,Pakistan
Altaf Alam Sheikh Zaid Hospital, Lahore - Pakistan
Zaigham Abbas Zia-ud-Din Hospital, Karachi - Pakistan
Altaf Baqir Naqvi Medicare Hospital Multan - Pakistan.
Bader Faiyaz Zuberi Dow Medical College, Dow University of Health Sciences,Karachi, Pakistan
Arif Amir Nawaz FMH College of Medicine and Dentistry, Lahore - Pakistan
Anwaar A Khan Doctors Hospital, Lahore -,Pakistan
Zahid Yaseen Hashmi Liver Center, Faisalabad - Pakistan
Asad Ali Chaudhry Gujranwala Liver Foundation, Siddiq Sadi Hospital,Gujranwala -,Pakistan
Zahid Azam NILGID, Dow University of Health Sciences, Karachi - Pakistan
Muhammed Salih Shifa International Hospital, Islamabad - Pakistan.
Bushra Ali FMH College of Medicine and Dentistry, Lahore - Pakistan
Masood Siddiq Jinnah Memorial Hospital, Rawalpindi, Pakistan
Lubna Kamani Liaqat National Hospital,Karachi -,Pakistan
Zeeshan Ali Sheikh Zaid Hospital, Lahore - Pakistan
Aftab Haider Sheikh Zaid Hospital, Lahore - Pakistan
Shahid Majid NILGID, Dow University of Health Sciences, Karachi - Pakistan
Abstract
In Pakistan, we have 4.9% prevalence of HCV in general population, with 79% genotype 3. Recently Sofosbuvir has been made available at compassionate price in Pakistan. Management of chronic hepatitis C includes counseling of HCV patients, their proper assessment to select those who need antiviral therapy, initiation of appropriate antiviral agents & duration of therapy, along-with careful monitoring for safety and efficacy. Hepatic status as well as previous history of HCV therapy needs to be taken in the consideration before starting antiviral therapy. Other factors include co-morbid conditions like obesity, DM, NASH, etc. Treatment of special populations like liver transplant patients, patients with HBV co-infection, chronic kidney disease and hemoglobinopathies need special considerations when initiating HCV therapy.
Publication Details
Page(s) 6-14
DOI DOI not available
Published Journal: Journal of Postgraduate Medical Institute, Volume: 30, Issue: 1, Year: 2016

Request the full text from PASTIC

Keywords
Hepatitis C, Sofosbuvir, HCV therapy
0

Citations

0

Downloads

61

Views